NCT05381311

Survey Based Discrete Choice Experiment Study in Prostate Cancer (DECIDER) Study

Prospective Evaluation of Patient Preferences for Outcomes of Hormonal Agents and Chemotherapy in Combination With Androgen Deprivation Therapy

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 1,020 (actual)
• Sponsor: Astellas Pharma Global Development, Inc. · Industry
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to quantify and publish participants' relative preferences for outcomes of chemotherapy and novel oral hormonal agents when added to androgen deprivation therapy (ADT) for participants with locally-advanced and metastatic hormone-sensitive prostate cancer (mHSPC). This study will also quantify the importance of administration factors related to convenience relative to treatment outcomes.

Detailed description

The study will develop and administer a discrete-choice experiment (DCE) to quantify tradeoff preferences of participants with mHSPC and locally-advanced prostate cancer in various countries. Data/surveys are being collected in: United States, Canada, UK, France, Spain, Japan, China and South Korea.

Conditions

• Prostate Cancer
• Metastatic Hormone-sensitive Prostate Cancer

Timeline

• Start date: 2021-09-03
• Primary completion: 2022-12-11
• Completion: 2022-12-11
• First posted: 2022-05-19
• Last updated: 2024-11-21

Locations

1 site across 1 country: United States